甲巯咪唑与丙硫氧嘧啶治疗甲状腺功能亢进患者的临床效果对比  

Comparative of the Clinical Efficacy of Methiomidazole and Promethazine in the Treatment of Hyperthyroidism

作　　者：孙雪萍 SUN Xueping(Department of Endocrinology,Dandong Hospital of Traditional Chinese Medicine,Dandong 118000,China)

机构地区：[1]丹东市中医院内分泌科,辽宁丹东118000

出　　处：《中国医药指南》2022年第9期38-41,共4页Guide of China Medicine

摘　　要：目的探讨甲巯咪唑与丙硫氧嘧啶治疗甲状腺功能亢进患者的临床效果,并将其治疗结果做对比,为后续甲亢患者治疗,提供实践依据。方法随机选择2017年9月至2019年3月医院内分泌科住院部收治的68例明确诊断为甲状腺功能亢进的患者,依据就诊顺序依次分为两组,各34例,两组在对症治疗基础上分别予以甲巯咪唑与丙硫氧嘧啶治疗,设为甲巯咪唑组与丙硫氧嘧啶组。治疗前后检测总三碘甲状腺原氮酸(TT_(3))、总甲状腺激素(TT_(4))、游离甲状腺素(FT_(4))、促甲状腺素(TSH)、甲状旁腺素(PTH)、甲状腺球蛋白抗体(TGAb)及骨钙素(BGP)水平,并进行对比分析。结果治疗后,甲巯咪唑组的TT_(3)为(1.64±0.58)μg/L、TT_(4)为(103.25±21.53)μg/L、FT_(4)为(103.25±21.53)pmol/L、TSH为(2.14±0.51)pmol/L,丙硫氧嘧啶组TT_(3)为(1.60±0.82)μg/L、TT_(4)为(105.77±17.49)μg/L、FT_(4)为(12.79±2.03)pmol/L、TSH为(2.10±0.69)pmol/L,差异无统计学意义(P>0.05)。甲巯咪唑组PTH为(67.62±5.48)ng/L、TGAb为(217.04±44.32)IU/L、BGP为(6.17±1.49)ng/L,丙硫氧嘧啶组分别为(66.13±7.19)ng/L、(223.26±37.51)IU/L、(6.41±1.55)ng/L,差异无统计学意义(P>0.05)。结论应用甲巯咪唑与丙硫氧嘧啶治疗甲状腺功能亢进患者均能够有效改善患者的甲状腺功能,纠正骨代谢紊乱,降低复发风险。Objective To explore the clinical effect of methimazole and propylthiouracil in the treatment of patients with hyperthyroidism,and compare the treatment results,so as to provide practical basis for the follow-up treatment of patients with hyperthyroidism.Methods Sixty-eight patients with hyperthyroidism,hereinafter referred to as hyperthyroidism,were randomly selected from the inpatient department of endocrinology of our hospital from September 2017 to March 2019.They were divided into two groups with 34 cases in each group according to the order of treatment.On the basis of symptomatic treatment,each group was treated with methimazole and propylthiouracil respectively,and set as methimazole group and propylthiouracil group.The levels of total triiodothyronitric acid(TT_(3)),total thyroid hormone(TT_(4)),free thyroxine(FT_(4)),thyrotropin(TSH),parathyroid hormone(PTH),thyroglobulin antibody(TGAb)and osteocalcin(BGP)were measured before and after treatment.Results After treatment,the TT_(3) of methimazole group was(1.64±0.58)μg/L,TT_(4) was(103.25±21.53)μg/L,FT_(4) was(103.25±21.53)pmol/L,TSH was(2.14±0.51)pmol/L,and TT_(3) of propylthiouracil group was(1.60±0.82)pmol/L,and TT_(4) was(105.77±17.49)μg/L,FT_(4)was(12.79±2.03)pmol/L,TSH was(2.10±0.69)pmol/L,there were no significant differences(P>0.05).The PTH was(67.62±5.48)ng/L,TGAb was(217.04±44.32)IU/L and BGP was(6.17±1.49)ng/L in methimazole group,and(66.13±7.19)ng/L,(223.26±37.51)IU/L and(6.41±1.55)ng/L in propylthiouracil group,respectively,which were not statistically significant(P>0.05).Conclusion Both methimazole and propylthiouracil in the treatment of hyperthyroidism can effectively improve thyroid function,correct bone metabolic disorder and reduce the risk of recurrence.

关 键 词：甲状腺功能亢进 甲巯咪唑 丙硫氧嘧啶 复发 

分 类 号：R581.1[医药卫生—内分泌]